Promoter methylation of RUNX3 was closely associated with patient age (Mann-Whitney test, p<0.001), tumour malignancy grade (χ2 test, p<0.001), and total patient survival (Mann-Whitney test, p<0.001) as well as patient 2-year patient survival after tumour resection (≤24 and >24 months; χ2 test, p=0.001). This evidence concerns the gene RUNX3 and neoplasm.